盟科药业：控股股东将变更为海鲸药业

Core Viewpoint - Amgen Pharmaceuticals announced a share subscription agreement with Nanjing Haijing Pharmaceutical Co., Ltd., which will result in Haijing holding 20% of Amgen's shares and becoming the controlling shareholder, with Zhang Xiantao as the actual controller [1]. Group 1 - Haijing Pharmaceutical plans to subscribe for 164 million shares of Amgen [1]. - The completion of this issuance will not trigger a mandatory tender offer [1]. - This equity change is classified as an increase in shareholding [1].